Skip to main content
. 2018 Apr 20;9(30):21613–21627. doi: 10.18632/oncotarget.25085

Figure 2. Proportion of studies in 2014-2016 that employed conventional chemotherapies.

Figure 2

Gemcitabine- and fluoropyrimidine-based therapies were highly utilized in clinical trials, with increases seen in the employment of the latter over these 3 years. There were also increases in the utilization of the FOLFIRINOX and gemcitabine+nab-paclitaxel combinations in the same time period.